Nick Leschly

President & Chief Executive Officer at bluebird bio, Inc.

Nick Leschly

Nick Leschly

President & Chief Executive Officer at bluebird bio, Inc.

Overview
Career Highlights

bluebird bio, Inc.
FierceBiotech
MedXtend Corporation

RelSci Relationships

1462

Number of Boards

8

Birthday

1973

Age

46

Relationships
RelSci Relationships are individuals Nick Leschly likely has professional access to. A relationship does not necessarily indicate a personal connection.

General Partner at GV Management Co. LLC

Relationship likelihood: Strong

Executive Chairman at Surface Oncology, Inc.

Relationship likelihood: Strong

Former Chief Marketing Officer at Bristol-Myers Squibb Company

Relationship likelihood: Strong

Managing Partner at Forbion Capital Partners Management Holding BV

Relationship likelihood: Strong

Founder at Synlogic, Inc.

Relationship likelihood: Strong

Partner, Washington DC at New Enterprise Associates

Relationship likelihood: Strong

Executive Chairman at Synlogic, Inc.

Relationship likelihood: Strong

Co-Founder at Third Rock Ventures LLC

Relationship likelihood: Strong

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

General Partner at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Paths to Nick Leschly
Potential Connections via
Relationship Science
You
Nick Leschly
President & Chief Executive Officer at bluebird bio, Inc.
Family Members
Parent
Founder at Care Capital LLC

Care Capital focuses on investments in later-stage biotechnology and specialty pharmaceutical companies. The firm looks for companies that are developing pharmaceutical assets and whose lead products have reached late-preclinical or early clinical development. Initial investments typically range from $5 million to $20 million. Care Capital participates in a variety of types of investments including growth capital and acquisitions of private, corporate-owned or public companies.

Parent-In-Law
Founding Partner Emeritus at Accel Partners LLC

Accel Partners focuses on investments in the following sectors: computing/storage, infrastructure, consumer Internet & media, energy, enterprise software/services, healthcare, biotechnology, mobile/wireless, networking systems, consumer retail, security, semiconductors and technology-enabled services.

Education
MBA
Class of 2000

The Wharton School is the business school of the University of Pennsylvania, an Ivy League university in Philadelphia, Pennsylvania. Wharton was the world’s first collegiate business school and the first business school in the United States. It was established in 1881 through a donation of Joseph Wharton.

BS Molecular Biology
Class of 1994

Princeton University is a vibrant community of scholarship and learning that stands in the nation's service and in the service of all nations. Chartered in 1746, Princeton is the fourth-oldest college in the United States. Princeton is an independent, coeducational, nondenominational institution that provides undergraduate and graduate instruction in the humanities, social sciences, natural sciences and engineering. As a world-renowned research university, Princeton seeks to achieve the highest levels of distinction in the discovery and transmission of knowledge and understanding. At the same time, Princeton is distinctive among research universities in its commitment to undergraduate teaching. Today, more than 1,100 faculty members instruct approximately 5,000 undergraduate students and 2,500 graduate students. The University's generous financial aid program ensures that talented students from all economic backgrounds can afford a Princeton education.

Career History
President & Chief Executive Officer
2010 - Current

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Partner
2007 - 2010

Third Rock invests in early-stage product-focused life science companies, particularly biotechnology, biopharmaceutical and medical device companies. They look for companies with high-growth potential that are well-positioned to bring about change in the marketplace. The firm focuses on transformative life sciences companies in areas of disruptive science likely to make a difference in the lives of patients. Third Rock actively engages with their portfolio companies to provide hands-on support.

Professional
2001 - 2006

Takeda Oncology Co. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Boards & Committees
Board Chairman
Current
Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$500 - $999
2008

REGIS COLLEGE EDUCATES APPROXIMATELY 2,070 UNDERGRADUATE AND GRADUATE STUDENTS IN DAYTIME, EVENING, AND WEEKEND PROGRAMS IN TWO SCHOOLS; THE SCHOOL OF NURSING, SCIENCE AND HEALTH PROFESSIONS AND THE SCHOOL OF LIBERAL ARTS, EDUCATION AND SOCIAL SCIENCE, AND CONTINUING STUDIES FOR ADULT LEARNERS. THE COLLEGE OPERATES A LIBRARY, FINE ARTS CENTER, LANGUAGE AND TECHNOLOGY LABS, AUDIO VISUAL SERVICES, HEALTH CENTER, ADMISSION, CAREER PLANNING, CAMPUS SAFETY, TRANSPORTATION, CAMPUS MINISTRY, INTER-COLLEGIATE ATHLETICS, REGISTRATION SERVICES, DINING, RESIDENT HALLS, CHILDRENS LEARNING CENTER, BOOKSTORE, AND A VARIETY OF OTHER STUDENT SERVICES.

Transactions
Details Hidden

bluebird bio, Inc. raised money in a private placement transaction

Details Hidden

bluebird bio, Inc. raised money in a private placement transaction

Details Hidden

bluebird bio, Inc. raised money in a private placement transaction

Investments
Details Hidden

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Nick Leschly. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Nick Leschly's profile does not indicate a business or promotional relationship of any kind between RelSci and Nick Leschly.